Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 08, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships

Castle is supporting key educational programs and initiatives throughout April in recognition of Esophageal Cancer Awareness Month.
April 07, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year

Castle announces 4th Top Workplaces USA win, ranking 30th of 358 U.S. companies with 500-999 employees
April 03, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test

Castle announced the recent publication of prospective data demonstrating the significant impact of DecisionDx-Melanoma on SLNB decision-making.
April 01, 2025 16:30 ET | Source: Castle Biosciences, Inc.

Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma

Castle will present data on DecisionDx-Melanoma at the 11th World Congress of Melanoma and 21st European Association of Dermato-Oncology (EADO) Congress.
March 28, 2025 16:15 ET | Source: Castle Biosciences, Inc.

Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups

Castle Biosciences will share new data on DecisionDx-SCC and DecisionDx-Melanoma at the NCCN 2025 Annual Conference.

keyboard_arrow_left Previous Page